NasdaqGS:IBRXBiotechs
ImmunityBio (IBRX) Is Up 12.8% After NCCN Expands ANKTIVA Bladder Cancer Guideline Inclusion - What's Changed
In March 2026, ImmunityBio reported that the National Comprehensive Cancer Network updated its bladder cancer guidelines to include ANKTIVA plus BCG for BCG-unresponsive non-muscle invasive bladder cancer with papillary-only disease, extending beyond the therapy’s current U.S. FDA-approved indication in carcinoma in situ.
This guideline expansion effectively validates ANKTIVA’s role in a broader bladder cancer population, potentially influencing physician treatment choices and payer coverage...